Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6

PHASE3CompletedINTERVENTIONAL
Enrollment

535

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Chronic Hepatitis C
Interventions
DRUG

48-weeks course

patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks

DRUG

Ribavirin

patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks

DRUG

Peginterferon alfa2a

patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks

DRUG

Ribavirin

patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks

Trial Locations (3)

510000

The Eighth People's Hospital of Guangzhou, Guangzhou

510630

The Third Affliated Hospital of Sun Yat-sen University, Guangzhou

Unknown

Zhongshan second people's hospital, Zhongshan

All Listed Sponsors
lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT01433887 - Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6 | Biotech Hunter | Biotech Hunter